Cargando…

Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies

Hochuekkito (HET), Juzentaihoto (JTT), and Ninjin'yoeito (NYT) have been used as Hozai, a group of traditional Japanese herbal medicines, to treat physically and mentally weak cancer patients. Their compositions are quite different, and Japanese pharmaceutical companies have been using differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiyomi, Anna, Matsuda, Ayaka, Nara, Moeko, Yamazaki, Kyosuke, Imai, Shinobu, Sugiura, Munetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476247/
https://www.ncbi.nlm.nih.gov/pubmed/34589133
http://dx.doi.org/10.1155/2021/7605057
_version_ 1784575566596276224
author Kiyomi, Anna
Matsuda, Ayaka
Nara, Moeko
Yamazaki, Kyosuke
Imai, Shinobu
Sugiura, Munetoshi
author_facet Kiyomi, Anna
Matsuda, Ayaka
Nara, Moeko
Yamazaki, Kyosuke
Imai, Shinobu
Sugiura, Munetoshi
author_sort Kiyomi, Anna
collection PubMed
description Hochuekkito (HET), Juzentaihoto (JTT), and Ninjin'yoeito (NYT) have been used as Hozai, a group of traditional Japanese herbal medicines, to treat physically and mentally weak cancer patients. Their compositions are quite different, and Japanese pharmaceutical companies have been using different types or quantities of herbs for formulations with the same name. Here, we compared the immunological differences between HET, JTT, and NYT with respect to the induced T cell subsets and cytokines. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and treated with 0 (control), 25, 50, 100, 200, or 400 μg/mL HET, JTT, or NYT (manufactured by Tsumura [TJ], Kracie [KR], and Kotaro [KO]). PBMC proliferation, CD4(+) T cell, CD8(+) T cell, and regulatory T cell (Treg) proportions and interleukin (IL) concentrations (IL-6, IL-10, IL-17A, interferon-γ, tumor necrosis factor-α, and transforming growth factor (TGF)-β) secreted by PBMCs were measured using Cell Counting Kit-8 or flow cytometry bead analysis. PBMC proliferation and CD4(+) T cell percentages were similar in the HET, JTT, NYT, and control groups; however, the percentage of CD8(+) T cells tended to increase after treatments. Tregs were suppressed by HET, JTT, and NYT, and TJ-JTT significantly decreased Treg numbers (compared with control). The concentrations of all cytokines except TGF-β were increased in a concentration-dependent manner (p < 0.05); particularly, KR-HET induced IL-6 secretion (compared with the control, TJ-HET, and KO-HET; 37-, 7-, and 17-fold, respectively; p < 0.05). The TGF-β concentration was decreased in a concentration-dependent manner by HET, JTT, and NYT (compared with the control). These results suggest that, compared with TJ-HET and KO-HET, KR-HET should be administered with caution. Although HET, JTT, and NYT belong to the same Hozai group and have the same names among companies, their differing effects on immune activity must be considered and they must be administered with caution.
format Online
Article
Text
id pubmed-8476247
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84762472021-09-28 Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies Kiyomi, Anna Matsuda, Ayaka Nara, Moeko Yamazaki, Kyosuke Imai, Shinobu Sugiura, Munetoshi Evid Based Complement Alternat Med Research Article Hochuekkito (HET), Juzentaihoto (JTT), and Ninjin'yoeito (NYT) have been used as Hozai, a group of traditional Japanese herbal medicines, to treat physically and mentally weak cancer patients. Their compositions are quite different, and Japanese pharmaceutical companies have been using different types or quantities of herbs for formulations with the same name. Here, we compared the immunological differences between HET, JTT, and NYT with respect to the induced T cell subsets and cytokines. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers and treated with 0 (control), 25, 50, 100, 200, or 400 μg/mL HET, JTT, or NYT (manufactured by Tsumura [TJ], Kracie [KR], and Kotaro [KO]). PBMC proliferation, CD4(+) T cell, CD8(+) T cell, and regulatory T cell (Treg) proportions and interleukin (IL) concentrations (IL-6, IL-10, IL-17A, interferon-γ, tumor necrosis factor-α, and transforming growth factor (TGF)-β) secreted by PBMCs were measured using Cell Counting Kit-8 or flow cytometry bead analysis. PBMC proliferation and CD4(+) T cell percentages were similar in the HET, JTT, NYT, and control groups; however, the percentage of CD8(+) T cells tended to increase after treatments. Tregs were suppressed by HET, JTT, and NYT, and TJ-JTT significantly decreased Treg numbers (compared with control). The concentrations of all cytokines except TGF-β were increased in a concentration-dependent manner (p < 0.05); particularly, KR-HET induced IL-6 secretion (compared with the control, TJ-HET, and KO-HET; 37-, 7-, and 17-fold, respectively; p < 0.05). The TGF-β concentration was decreased in a concentration-dependent manner by HET, JTT, and NYT (compared with the control). These results suggest that, compared with TJ-HET and KO-HET, KR-HET should be administered with caution. Although HET, JTT, and NYT belong to the same Hozai group and have the same names among companies, their differing effects on immune activity must be considered and they must be administered with caution. Hindawi 2021-09-18 /pmc/articles/PMC8476247/ /pubmed/34589133 http://dx.doi.org/10.1155/2021/7605057 Text en Copyright © 2021 Anna Kiyomi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kiyomi, Anna
Matsuda, Ayaka
Nara, Moeko
Yamazaki, Kyosuke
Imai, Shinobu
Sugiura, Munetoshi
Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies
title Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies
title_full Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies
title_fullStr Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies
title_full_unstemmed Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies
title_short Immunological Differences in Human Peripheral Blood Mononuclear Cells Treated with Traditional Japanese Herbal Medicines Hochuekkito, Juzentaihoto, and Ninjin'yoeito from Different Pharmaceutical Companies
title_sort immunological differences in human peripheral blood mononuclear cells treated with traditional japanese herbal medicines hochuekkito, juzentaihoto, and ninjin'yoeito from different pharmaceutical companies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476247/
https://www.ncbi.nlm.nih.gov/pubmed/34589133
http://dx.doi.org/10.1155/2021/7605057
work_keys_str_mv AT kiyomianna immunologicaldifferencesinhumanperipheralbloodmononuclearcellstreatedwithtraditionaljapaneseherbalmedicineshochuekkitojuzentaihotoandninjinyoeitofromdifferentpharmaceuticalcompanies
AT matsudaayaka immunologicaldifferencesinhumanperipheralbloodmononuclearcellstreatedwithtraditionaljapaneseherbalmedicineshochuekkitojuzentaihotoandninjinyoeitofromdifferentpharmaceuticalcompanies
AT naramoeko immunologicaldifferencesinhumanperipheralbloodmononuclearcellstreatedwithtraditionaljapaneseherbalmedicineshochuekkitojuzentaihotoandninjinyoeitofromdifferentpharmaceuticalcompanies
AT yamazakikyosuke immunologicaldifferencesinhumanperipheralbloodmononuclearcellstreatedwithtraditionaljapaneseherbalmedicineshochuekkitojuzentaihotoandninjinyoeitofromdifferentpharmaceuticalcompanies
AT imaishinobu immunologicaldifferencesinhumanperipheralbloodmononuclearcellstreatedwithtraditionaljapaneseherbalmedicineshochuekkitojuzentaihotoandninjinyoeitofromdifferentpharmaceuticalcompanies
AT sugiuramunetoshi immunologicaldifferencesinhumanperipheralbloodmononuclearcellstreatedwithtraditionaljapaneseherbalmedicineshochuekkitojuzentaihotoandninjinyoeitofromdifferentpharmaceuticalcompanies